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Abstract: Recent advances in molecular biology combined with the wealth of information generated by the Human Ge-
nome Project have fostered the emergence of nutrigenomics, a new discipline in the field of nutritional research. Nutrige-
nomics may provide the strategies for the development of safe and effective dietary interventions against the obesity epi-
demic. According to the World Health Organization, more than 60% of the global disease burden will be attributed to 
chronic disorders associated with obesity by 2020. Meanwhile in the US, the prevalence of obesity has doubled in adults 
and tripled in children during the past three decades. In this regard, a number of natural dietary supplements and micronu-
trients have been studied for their potential in weight management. Among these supplements, (–)-hydroxycitric acid 
(HCA), a natural extract isolated from the dried fruit rind of Garcinia cambogia, and the micronutrient niacin-bound 
chromium(III) (NBC) have been shown to be safe and efficacious for weight loss. Utilizing cDNA microarrays, we dem-
onstrated for the first time that HCA-supplementation altered the expression of genes involved in lipolytic and adipogenic 
pathways in adipocytes from obese women and up-regulated the expression of serotonin receptor gene in the abdominal 
fat of rats. Similarly, we showed that NBC-supplementation up-regulated the expression of myogenic genes while sup-
pressed the expression of genes that are highly expressed in brown adipose tissue in diabetic obese mice. The potential 
biological mechanisms underlying the observed beneficial effects of these supplements as elucidated by the state-of-the-
art nutrigenomic technologies will be systematically discussed in this review. 
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1. INTRODUCTION 
  With the success of the Human Genome Project and the 
advances in molecular biology, a new discipline, namely 
nutrigenomics, in the field of nutrition research has emerged 
[1, 2]. This new wave of molecular nutrition, which unfolds 
the mystery behind nutrition-gene interactions, may provide 
the strategies for developing safe and effective nutritherapies 
for individuals such as those who are under siege by the obe-
sity epidemic [3, 4]. The World Health Organization (WHO) 
coined the term globesity to signify the fact that obesity has 
rapidly grown into a global epidemic in recent years [5-7]. 
According to WHO, more than 60% of the global disease 
burden will be attributed to chronic disorders associated with 
obesity in the year 2020 [8]. Meanwhile in the US, the 
prevalence of obesity has doubled in adults and tripled in 
children during the past three decades [9-12]. Currently, the 
number of overweight and obese US adults surpasses that of 
the normal weight US adults for the first time in history [13, 
14]. This trend is expected to continue at an alarming rate 
with an estimated annual increase of up to 0.9% [15]. As a 
result, it is projected that 75% of the US adults will be over-
weight or obese by the year 2015 [15].  
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  Since food is the central component contributing to obe-
sity, a long-term lifestyle change in diet in conjunction with 
exercise may present a cost-effective first-line of interven-
tion for obesity [16, 17]. To reflect the need for individual-
ized nutritional plans, the United States Department of Agri-
culture (USDA) has recently replaced its Food Guide Pyra-
mid with MyPyramid emphasizing on whole grains, fruits 
and vegetables [18]. Indeed, there are a number of natural 
dietary supplements and trace elements that may be used as a 
part of nutritional lifestyle intervention for weight manage-
ment [19]. In this regard, (–)-hydroxycitric acid (HCA), a 
natural extract isolated from the dried fruit rind of Garcinia 
cambogia, and the trace metal chromium(III) have been 
shown, in animal models and clinical trials, to be safe and 
efficacious as weight loss supplements [20, 21]. This chapter 
will discuss the potential biological mechanisms underlying 
the observed beneficial effects of these supplements as elu-
cidated by the state-of-the-art nutrigenomic technologies. 
2. NUTRIGENOMICS: THE NEW FRONTIER OF 
NUTRITIONAL SCIENCE 
2.1. Definition and Scope of Nutrigenomics and Nutrige-
netics  
  Nutrigenomics is the study of the effect of nutrition or 
dietary components on the transcriptome of cells and tissues.  
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The broad scope of nutrigenomics involves studying the ef-
fect of nutrition or dietary components on the structure, in-
tegrity and function of the genome. It is an offshoot of the 
science of genomics, and is being shaped by the evolving 
and powerful genomic technologies. It helps to understand 
how bioactive dietary components influence the human ge-
nome by altering the transcriptome or gene expression pro-
file [22].  
  The term nutrigenetics is sometimes used interchangea-
bly with nutrigenomics. However, nutrigenetics is the retro-
spective investigation of how genetic variations such as sin-
gle nucleotide polymorphisms (SNPs) in haplotype maps 
(HapMap) give rise to differences in response to specific 
nutrients and eventually lead to differences in health and 
disease status among individuals [23, 24]. Fig. (1) illustrates 
the distinctions between nutrigenomics and nutrigenetics in 
simple terms. This chapter will focus on the application of 
nutrigenomics to weight management. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig (1). Distinctions between nutrigenomics and nutrigenetics. The 
investigation of how food components modulate changes in gene 
expression profile or transcriptome is defined as nutrigenomics. 
One the other hand, nutrigenetics is defined as the study of how 
genetic variations such as single nucleotide polymorphism (SNP) 
among individuals affect their response to specific food compo-
nents. 
2.2. Nutrigenomics and Obesity  
  Accumulating evidence has indicated that dietary com-
ponents not only fuel the body but also participate in the 
modulation of gene expression [25]. Therefore, nutrigenom-
ics represents the future of nutritional research. In fact, re-
cent surveys have projected that 33% of the US consumers 
will be collecting and acting on nutrigenomic information by 
the year 2010 [26].  
  One of the pressing issues faced by the nutrition research 
community is the obesity epidemic. Nutrigenomics ap-
proaches have been initiated for obesity research and the data 
from each of these studies will provide new insights into the 
mechanisms of nutrient-gene interaction [27].  
2.2.1. Obesity Epidemic and Socioeconomic Burden 
  The World Health Organization (WHO) defines over-
weight and obese by body-mass index (BMI, kg/m
2) cutoff 
points of 25 and 30, respectively [15]. Globally, it is esti-
mated that 1.6 billion adults are overweight while 400 mil-
lion are obese [28]. In the US, the estimated number of 
overweight and obese adults has recently surpassed that of 
their normal weight counterparts [1, 15, 29]. This alarming 
increase in the prevalence of obesity may be attributable to 
lifestyle changes in modern society favoring decreased activ-
ity and increased food consumption, thus creating a fertile 
obesogenic environment [7]. The national financial impact 
from obesity epidemic is tremendous. According to the Sur-
geon General, the direct and indirect costs of obesity were 
approximately $120 billion in the turn of the millennium 
[30]. 
2.2.2. Obesity Etiology  
  Although the fundamentals of energy imbalance in obe-
sity are well accepted, the complex factors affecting this 
disequilibrium remain unclear [7, 31].  
  Even though it is quite inconceivable to entertain the no-
tion that obesity might be caused by infectious agents, sev-
eral studies have indicated that human adipogenic adenovi-
ruses and human gut microbes such as Bacteriodetes and 
Firmicutes may represent additional contributing factors to 
human obesity [32-36]. Thus, the etiology and pathogenesis 
of obesity may comprise a myriad of hitherto unknown fac-
tors that influence the imbalance of energy consumption and 
its expenditure.  
2.2.3. Obesity-Related Disorders  
  The consequences of obesity are that they significantly 
decrease the quality of life and life expectancy while greatly 
increase the risk for a number of diseases related to increased 
morbidity and mortality [37-39]. An estimated loss of life 
expectancy by 7 years has been attributed to obesity at age 
40 [38].  
  The mounting challenge of obesity epidemic is its asso-
ciation with a broad spectrum of metabolic disorders such as 
type II diabetes and cardiovascular disease, and certain can-
cers including colon cancer and breast cancer [40, 41]. The 
statistics for the correlation of obesity to these disorders are 
staggering: 80% of type II diabetes, 70% of cardiovascular 
diseases, and 42% of breast and colon cancer have been 
linked to obesity [21, 42, 43]. Also, 85% of the children di-
agnosed with type II diabetes are classified as obese [21]. 
Indeed, the dependency of type II diabetes on obesity is so 
strong that the term “diabesity” has been coined for this phe-
nomenon [44, 45]. Hence, elevated BMI results in significant 
increases in the disease risks and health care costs [46, 47].  
2.2.4. Weight Management  
  Accumulating evidence indicates that obesity-related risk 
factors are not only preventable but also ameliorable through 
weight loss and long-term weight management programs 
[48-50]. Since the root of this ever-growing obesity epidemic 
seems to link intimately with increased food consumption, 
the therapeutic goals for weight loss and weight management 
are to curb appetite, reduce food intake, and decrease fat 
absorption and increase fat oxidation [17, 51]. Three key 
strategies of weight interventions are commonly used 
worldwide to combat the obesity epidemic [46]: (1) bariatric 
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ple suffering from severe clinical obesity, (2) pharmacother-
apy, which is the use of anti-obesity drugs, such as rimona-
bant, phentermine, sibutramine, and orlistat [52, 53], and (3) 
life-style interventions, which include diet and exercise, as 
well as use of various anti-obesity nutritional supplements 
which have been thoroughly studied and have been proved to 
be safe and efficacious.  
  In the following text, the discussion will be restricted to 
two such nutritional supplements that have been used for 
weight management. These are niacin-bound chromium(III) 
complex (ChromeMate®, NBC) and (–)-hydroxycitric acid 
(Super CitriMax®, HCA-SX).  
  A number of biochemical, pharmacological and toxico-
logical studies have been conducted to show that niacin-
bound chromium(III) complex as a novel micronutrient is 
capable of reducing body fat mass while increasing lean 
body mass [20, 54]. The (–)-hydroxycitric acid (HCA) is a 
natural extract from the dried fruit rind of Garcinia cambo-
gia. Numerous studies have demonstrated that a novel cal-
cium-potassium double salt of 60% HCA preparation (HCA-
SX) is safe, bioavailable and efficacious in promoting 
healthy body weight.  
2.2.5. Nutritional Supplements 
  There is a plethora of weight management dietary sup-
plements on the market. The common claims of these prod-
ucts include increase in energy expenditure, satiety and fat 
oxidation, and decrease in fat absorption. However, the effi-
cacy and safety for many of these dietary supplements have 
not been systematically and scientifically investigated. 
Therefore, the U.S. Food and Drug Administration (FDA) 
has taken regulatory actions against a number of dietary sup-
plements.  
  On the contrary, a number of biochemical, pharmacol-
ogical and toxicological studies have been conducted to 
show that niacin-bound chromium(III) complex is a novel 
micronutrient that is capable of reducing body fat mass while 
increasing lean body mass [20, 54]. NBC has also been 
shown to be effective in diminishing the obesity-related risk 
factors of metabolic syndrome by promoting glucose-insulin 
sensitivity [55-57]. The importance of chromium(III) was 
revealed five decades ago with the discovery that chro-
mium(III) is the central component of the biologically active 
form of glucose tolerance factor (GTF) found in Brewer’s 
yeast [58, 59]. GTF prevented diabetes in experimental ani-
mals by potentiating the action of insulin and modulating 
protein, fat and carbohydrate metabolism [60].  
  A comparative clinical study evaluating the effects of 
chromium(III) supplements (NBC and chromium(III) picoli-
nate) with or without exercise training in young, obese 
women showed that exercise training combined with NBC 
supplementation was associated with significant weight loss 
and lowered insulin response to an oral glucose load [61]. In 
contrast, chromium(III) picolinate supplementation resulted 
in a significant weight gain. Therefore, NBC supplementa-
tion combined with exercise training proved to be beneficial 
for weight loss and for the reduction of risk factors associ-
ated with diabetes [61]. 
  A subsequent randomized, double-blind, placebo-con- 
trolled, crossover study on 20 overweight African-American 
women has showed that subjects taking 200 g NBC three 
times daily exhibited a significant fat loss without causing a 
reduction in lean body mass as compared to subjects receiv-
ing placebo [62].  
   The other extensively studied weight management herbal 
supplement is the (–)-hydroxycitric acid (HCA), a natural 
extract from the dried fruit rind of Garcinia cambogia. Nu-
merous studies have demonstrated that a novel calcium-
potassium double salt of 60% HCA preparation (HCA-SX) is 
safe, bioavailable and efficacious in promoting healthy body 
weight. The unique structural characteristics of HCA-SX 
make it completely water soluble and highly bioavailable, as 
well as tasteless, odorless and colorless in solution [63-70].  
  A randomized, placebo-controlled, double-blind study on 
the beneficial effect of HCA-SX was conducted in 54 male 
and female subjects who were 15-45% overweight [71]. The 
subjects in the treatment group (n=30) of this eight-week 
study were given Lipodex-2™ (500 mg of Garcinia cambo-
gia extract and 100 g elemental chromium as NBC) 3 times 
a day and the subjects in the control group (n=24) received 
the placebo. All subjects were encouraged to adhere to a 
low-fat diet plan (1,200 kcal diet/day) and to drink 64 oz of 
water per day. The participants in the treatment group lost an 
average of 11.14 pounds/person while those in the control 
group lost an average of 4.2 pounds/person [71]. 
 A  subsequent eight-week randomized, placebo-controlled, 
double-blind study was conducted in sixty obese subjects 
[72]. Subjects received either the placebo (n=30) or HCA 
(n=30). The dose for HCA was 400 mg three times daily 30 
minutes before each meal. All subjects were on a low-fat diet 
of 1,200 kcal/day and were instructed to exercise 3 times a 
week for 8 weeks. The HCA-supplemented group exhibited 
a significant weight loss as compared to the placebo group. 
The composition of the weight loss, determined by the near 
infra-red (NIR) technique, showed that 87% of the weight 
loss in the HCA group is due to fat loss. Appetite scores 
were also significantly reduced in the HCA group [72].  
  The underlying molecular mechanisms for the observed 
benefits of NBC and HCA-SX on weight loss were largely 
unclear. However, the advent of nutrigenomics opens up a 
new avenue for the elucidation of nutrition-gene interactions 
that will aid in the design of new nutritherapeutic strategies 
for weight management. 
3. APPLICATION OF NUTRIGENOMICS IN WEIGHT 
MANAGEMENT 
3.1. Chromium(III)-Gene Interaction  
  Numerous animal and human clinical studies have estab-
lished the safety and efficacy of chromium(III) supplementa-
tion in combating insulin resistance, reducing body fat and 
increasing lean body mass [20, 54]. However, the underlying 
molecular mechanism for the observed beneficial effects of 
chromium(III) is unclear. In contrast, the structure, function, 
and mode of action of the majority of other essential trace 
elements such as copper and zinc have been well character-
ized. Even though there have been several attempts to iden-
tify the specific organic chromium(III) complex that exhibits 
biological functions, the results have generally been contro-
versial at best [73-76].  242    Current Genomics, 2008, Vol. 9, No. 4  Lau et al. 
  In order to decipher the mechanism modulating the ge-
netic response to NBC-supplementation, a recent study util-
ized the high-throughput screening (HTS) technology to ex-
amine NBC-induced alteration in gene expression profiles 
(transcriptome) [77]. This study investigated the effect of 
oral NBC supplementation on the physiological parameters 
of obese mice homozygous for Type II diabetes spontaneous 
mutation (Lepr
db), and the alteration in transcriptome of sub-
cutaneous adipose tissues in these obese mice [77]. Supple-
mentation regimen was carried for 10 weeks in male Lepr
db 
mice which were randomly divided into the NBC (n=7, 
NBC) or placebo (n=7, PBO) group.  
  Blood samples were drawn from the mice before (base-
line) and after 6 weeks of supplementation. Blood glucose 
level as well as lipid profile parameters such as total choles-
terol (TC), HDL cholesterol (HDLC), triglycerides, LDL, 
and the TC-to-HDLC ratio were assessed at week 6 and 
compared to baseline data collected before any supplementa-
tion. After 8 weeks of supplementation, oral glucose toler-
ance test (OGTT) was performed by challenging the mice 
with 1.5 mg/g body weight of glucose solution and measur-
ing blood glucose levels at 30, 60, and 120 min after glucose 
challenge [77]. At 10 weeks post-supplementation, mice 
were euthanized and subcutaneous fat was removed for iso-
lation of RNA. The quality of RNA was verified before the 
synthesis of targets from RNA for hybridization to probes 
(41,101 probe sets) on the mouse genome microarrays (430 
v2.0).  
  The results of biochemical tests, as summarized in Table 
1, showed that NBC-supplementation significantly attenu-
ated the levels of triglycerides, TC, LDL cholesterol, and 
TC-to-HDLC ratio in the plasma of the obese diabetic mice. 
The plasma level of HDLC in these mice was significantly 
increased by NBC-supplementation. OGTT findings indi-
cated a significant enhancement by NBC-supplementation in 
the rate of blood glucose clearance from 60 to 120 min after 
glucose challenge [77]. The observations from this study 
agreed with the previous findings in other human and animal 
studies that NBC supplementation play a beneficial role in 
glucose and lipid metabolism [77].  
 
Table  1.  Comparisons of Blood Lipid Profiles between Pla-
cebo Control and Niacin-Bound Chromium (NBC)-
Treated Obese Type 2 Diabetic Rats 
Placebo NBC 
Parameters (mg/dl) 
(Mean ± SD)  (Mean ± SD) 
Total Cholesterol  179 ± 11  144 ± 12** 
LDL Cholesterol  83 ± 11  38 ± 12** 
Triglycerides  100 ± 21  56 ± 12** 
HDL Cholesterol  76 ± 8  95 ± 3** 
Total/HDL Cholesterol  2.83 ± 0.31  1.51 ± 0.13** 
Lipid profiles were analyzed at week 6 post-supplementation. Data indicate mean ± 
S.D. with N=7 per group. **P < 0.0005, indicates statistical significance as compared 
to the placebo group [77].  
  NBC-induced changes in the transcriptome of subcutane-
ous adipose tissues of these obese diabetic mice were inter-
rogated by an unbiased genome-wide microarray approach in 
an attempt to identify candidate genes whose expressions 
were sensitive to NBC-supplementation [77]. The data-
mining scheme is presented in Fig. (2) where, among the 
45101 probe-sets interrogated, only a small subset of genes 
was found to be influenced by NBC-supplementation. The 
overall effect of NBC-supplementation on the genome of the 
adipose tissues was positive since it stimulated more genes 
than it inhibited them as illustrated by Fig. (3). The NBC-
induced genes are known to be involved in glycolysis, mus-
cle metabolism, and muscle development. The expression of 
muscle-specific genes in fat tissue over time has been shown 
to reduce fat content in the adipose tissues [78]. The NBC-
suppressed genes in the adipose tissues are known to play 
important roles in thermogenic process of brown fat tissue. 
On the whole, the microarray data indicated that NBC-
supplementation did not induce a genome-wide perturbation; 
rather, NBC-supplementation specifically influenced a small 
subset of genes that are biologically relevant to adipocyte 
maintenance.  
  As shown in Fig. (3), bioinformatic analyses of the mi-
croarray data resulted in 161 up-regulated and 91 down-
regulated genes by NBC-supplementation in obese diabetic 
mice. The expression of several biologically relevant candi-
date genes was further verified by real-time PCR and the 
results are summarized in Table 2. Enolase 3 (ENO3) showed 
the highest up-regulation (7.6-fold) compared to controls in 
the fat tissues, in response to NBC-supplementation. Enolase 
is a dimeric glycolytic enzyme that catalyzes the intercon-
version of 2-phosphoglycerate and phosphoenolpyruvate. 
Beta-enolase subunit is encoded by ENO3 gene and is re-
sponsible for more than 90% of the enolase activity in adult 
human muscle [79]. It has been shown that mutations in 
ENO3 led to -enolase deficiency that resulted in defects in 
glycolysis and metabolic myopathies [79]. Another glyco-
lytic gene, encoding the enzyme glucose phosphate isomerase 
(GPI), was also up-regulated in the NBC-supplemented 
obese diabetic mice. It has been documented that glycolytic 
genes such as ENO3 and GPI are down-regulated in the vis-
ceral adipose tissues of morbidly obese patients as compared 
to non-obese individuals [80]. Calsequestrin, the most abun-
dant calcium-binding protein in the sarcoplasmic reticulum 
of skeletal and cardiac muscle, was up-regulated by NBC-
supplementation. Since chromium has been demonstrated to 
enhance the expression of plasmalemmal calcium-ATPase in 
smooth muscle cells, it is possible that chromium may influ-
ence calcium homeostasis by increasing the calcium storage 
capacity through up-regulation of calsequestrin [81, 82]. 
Tropomyosin-1 (TPM1) gene, which encodes for the -
subunit (-tropomyosin) of the tropomyosin family of pro-
teins, was up-regulated in response to NBC-supplementation. 
TPM1 protein plays an important role in calcium-dependent 
regulation of striated muscle contraction [83-85]. Expression 
of these up-regulated genes in fat tissue over time has been 
shown to attenuate the fat content of the tissue [78].  
  The NBC-induced down-regulated genes included adipo-
cyte-specific genes such as the cell death-induced DNA frag- 
mentation factor (CIDEA), mitochondrial uncoupling protein 
1 (UCP1) and tocopherol transfer protein (TTP) (Table 2). Nutrigenomic Analysis of Weight Management Supplements  Current Genomics, 2008, Vol. 9, No. 4    243 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). GeneChip
® data analysis scheme. Type 2 Lepr
db obese diabetic mice were supplemented with NBC (n=4) or with placebo (n=4) for 
10 weeks. After 10-week supplementation, mice were euthanized and subcutaneous fat was removed for RNA extraction and microarray 
analysis. NBC-sensitive genes were identified by GeneChip
® mouse genome 430 v2.0 arrays from Affymatrix. Raw data were collected and 
analyzed with the Affymatrix Microarray Suite 5.0 (MAS) and Data Mining Tool 2.0 (DMT) softwares. The Student’s t-test was performed 
with DMT on data generated by MAS to identified genes whose expression was significantly changed (P<0.05) in the NBC-supplement group 
as compared to the control group. DNA-Chip analyzer (dChip) was used for probe-level analysis and creating hierarchical clustering of the 
post-DMT data with fold changes set at >1.2 and P-value of t-test set at <0.05 [92]. The up () and down () arrows indicate up- and down-
regulation of NBC, respectively. Image reproduced with permission from American Physiological Society [77]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Visualization of hierarchical clustering of genes in response to NBC treatment. Gene expression data were collected as described in 
Fig. (4) legend. Genes whose expression was significantly (P<0.05) altered between the control and the NBC-treated groups were chosen for 
hierarchical clustering analysis. Expression signal was represented by red to green gradient signifying high to low expression. 161 signifi-
cantly up-regulated genes (A) and 91 significantly down-regulated genes (B) were detected. Image used with permission from American 
Physiological Society [77]. 244    Current Genomics, 2008, Vol. 9, No. 4  Lau et al. 
Table 2.  Candidate Genes in Response to NBC-Supplementation 
Down-Regulated Genes*  Function 
Cell death-inducing DNA fragmentation factor  Lipid metabolism 
Uncoupling protein 1  Brown fat thermogenesis 
Tocopherol transfer protein  -tocopherol trafficking 
Up-Regulated Genes*  Function 
Enolase 3  Glycolysis and gluconeogenesis 
Calsequestrin 1  Calcium storage, muscle contraction 
Tropomyosin 1  calcium-regulated striatal muscle contraction 
Glucose phosphate isomerase 1  Glycolysis 
Candidate genes were identified by genome-wide microarray analysis. Genes shown in the table represent those whose altered expression was confirmed by quantitative real-time RT-
PCR (*P<0.05, as compared to control) [77].  
 
TTP protein is involved in the transport of -tocopherol from 
hepatocytes into peripheral tissues including adipose tissue 
[86]. Since -tocopherol severs as a potent antioxidant, 
down-regulation of TTP may decrease the lipid-phase anti-
oxidant defense in the adipose tissue thus promoting the 
breakdown of adipose tissues [77]. In addition, because -
tocopherol readily interconverts into lipoproteins and TTP is 
likely to facilitate the incorporation of -tocopherol into 
LDL [87, 88], down-regulation of TTP in the adipose tissues 
is expected to lower the levels of LDL. Interestingly, the 
physiological findings indicated that the plasma levels of 
LDL were indeed reduced as indicated in Table 1. Both 
CIDEA and UCP1 proteins are highly expressed in brown 
adipose tissue (BAT) and they play important roles in the 
thermogenesis and energy expenditure of BAT [89, 90]. 
CIDEA-knockout mice exhibited resistance to diet-induced 
obesity and diabetes [90]. Thus, down-regulation of CIDEA 
by NBC may exhibit similar effects, that is, weight loss and 
resistance to diet-induced obesity.  
  Taken together, the data suggest that NBC exerts its 
beneficial effects of weight loss through regulation of spe-
cific genes in the fat cells of obese diabetic mice [90]. Such 
genomic approach to nutritional research has paved the way 
for future investigations to unravel the molecular basis of 
chromium-gene interactions.  
3.2. HCA-Gene Modulation 
3.2.1. Animal Study  
  The effects of low-dose oral HCA-SX on the body 
weight and abdominal fat gene expression profile of Sprague 
Dawley rats were investigated [91]. The rats were randomly 
divided into the HCA-SX group and the control group; ani-
mals in the HCA-SX group were supplemented with 10 mg 
HCA-SX/kg body weight for eight weeks after which they 
were sacrificed. Plasma samples were collected for the as-
sessment of leptin level by ELISA, and abdominal fat was 
removed for microarray studies. No overt behavioral changes 
were observed in rats from the HCA-SX group compared to 
controls; however, a significant weight loss was observed in 
the HCA-SX group starting from week six and continued 
until the end of the HCA-SX supplementation period (week 
eight). Plasma leptin levels were not affected by HCA-SX 
supplementation, but transcription of the leptin gene in the 
abdominal fat cells from the HCA-SX group, as indicated by 
real-time RT-PCR, was significantly attenuated [91].  
  Genome-wide changes in gene expression profile follow-
ing HCA-SX treatment was studied using DNA microarray. 
Rat genome arrays containing 15,923 probe sets were 
screened for alterations in the transcriptome of abdominal fat 
induced by HCA-SX feeding. dChip-assisted [92] analysis of 
the expression data resulted in 93 up-regulated and 18 down-
regulated genes [91]. Three relevant HCA-SX–induced up-
regulated genes selected for further validation by real-time 
RT-PCR analysis were prostaglandin D synthase (PDS), al-
dolase B (AldB), and lipocalin (LCN2). The data from real-
time RT-PCR were in agreement with DNA microarrays 
[91]. To put these HCA-SX up-regulated genes into perspec-
tive as to how they could be modulated in specific signaling 
pathways, they were mapped to known pathways related to 
fat metabolism. Several bioinformatics tools such as Gen-
Mapp, KEGG (Kyoto Encyclopedia of Genes and Genomes) 
and Gene Ontology were used to reconstruct the pathways. 
This approach overlapped the candidate genes with the 
monoamine G-protein-coupled receptor pathway. Specifi-
cally, it was found that the serotonin receptor expression was 
consistently up-regulated in response to HCA-SX supple-
mentation in the abdominal fat. This discovery is consistent 
with the previous observation of the serotonergic property of 
HCA-SX that HCA-SX promotes serotonin release form 
isolated rat brain [93]. 
  One important finding was that HCA-SX supplementa-
tion selectively induced a small subset (approximately 1%) 
of all the genes screened in the abdominal fat. The expres-
sion of vital genes required for fundamental support of cellu-
lar functions was not affected by HCA-SX supplementation. 
Furthermore, the changes in the expression profile did not 
indicate any discernible stress or toxicity response to HCA-
SX supplementation [91]. Therefore, the results thus far con-
cur with prior findings to support the effective and safe use Nutrigenomic Analysis of Weight Management Supplements  Current Genomics, 2008, Vol. 9, No. 4    245 
of HCA-SX in weight loss and validated the previous obser-
vation for the serotonergic property of dietary HCA-SX sup-
plementation [93]. 
3.2.2. Human Adipocyte Study 
  Defects in the lipolytic process have been linked to hu-
man obesity [94]. Roy et al. (2007) sought to investigate the 
effects of HCA-SX on lipolysis in cultured human adipo-
cytes using biochemical and genomic approaches [95]. Sub-
cutaneous preadipocytes isolated from obese women were 
allowed to differentiate to adipocytes for two weeks in cul-
ture. The effects of HCA-SX on lipid metabolism and tran-
scriptomic profile were examined. HCA-SX treatment at the 
experimental conditions did not cause any cytotoxicity in the 
human adipocytes. Fig. (4) showed that HCA-SX treated 
adipocytic cells exhibited a significant increase in the fat 
droplet dispersion as compared to the control cells suggest-
ing that HCA-SX treatment potentiated lipolysis through 
mobilization of triacylglycerol storage. 
  In order to gain insight into the genome-wide effects of 
HCA-SX treatment on human adipocyte gene expression 
profile, human genome microarrays were used to compare 
the changes in the transcriptomes between the HCA-SX 
treated and control human adipocytes. The data acquisition 
and analysis processed were illustrated in Fig. (5). The hu-
man genome microarrays containing a total of 54,676 probe 
sets per chip were use to screen HCA-SX induced alterations 
in gene expression profiles of the human adipocytes. HCA-
SX treatment caused statistically significant changes in the 
transcriptome of a very small cluster of genes of which 348 
genes were significantly down-regulated while 366 genes 
were significantly up-regulated as demonstrated in Fig. (6).  
  The expression of selected HCA-SX responsive genes 
obtained by microarray analysis was independently verified 
by real-time RT-PCR (Table 3). Of these, the down-regula- 
ted perilipin gene was of particular interest. Perilipin protein, 
the product of the perilipin gene, coats the surfaces of lipid 
droplets in adipocytes and is found at lower levels surround-
ing lipid droplets in steroidogenic cells. Perilipin proteins 
drive triacylglycerol storage in adipocytes by regulating the 
rate of basal lipolysis [96]. HCA-SX–induced suppression of 
perilipin gene expression is likely to contribute to the ob-
served lipolytic effect of HCA-SX on lipid droplet dispersion 
as illustrated in Fig. (4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Effect of HCA-SX treatment on the formation of lipid droplets. Differentiated adipocytes from overweight non-diabetic women 
were cultured with or without HCA-SX (0.5 mg/mL) for 96 hours. After treatment, cells were fixed in 10% buffered formalin, stained with 
oil red O and images were recorded (A). Large oil droplets (indicated by yellow arrows) in each image were counted with Zeiss Axiovision 
software (B). Image reproduced with permission from Mary Ann Liebert, Incorporated [95]. 246    Current Genomics, 2008, Vol. 9, No. 4  Lau et al. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Flowchart of GeneChip® data analysis scheme. RNA was 
extracted from each sample and used to assess HCA-SX induced 
alterations in gene expression in human adipocytes with human 
genome microarray (U133 v2.0). Raw data were collected by 
GeneChip® operating software. Data contained in the .cel files 
were normalized by ArrayAssist® Expression software. The Ne-
tAffx™ software was used to identify fat-specific probes. This sub-
set was derived from the main subset with R 2.2.1 software. Genes 
whose expression was significantly (P<0.05) altered between the 
two groups were identified by the dChip software with the testing 
parameter values set as indicated in the diagram. FDR = false dis-
covery rate. Image used with permission from Mary Ann Liebert, 
Incorporated [95]. 
 Peroxisome proliferator-activated receptor (PPAR) gamma 
co-activator 1-alpha (PGC1-alpha) was also found to be 
down-regulated by HCA-SX in human adipocytes. PGC1-
alpha is a transcriptional co-activator protein that coordi-
nately regulates metabolic pathways; thus, it may play an 
important role in the pathogenic conditions such as obesity, 
diabetes, and cardiomyopathy [97]. It has been shown that 
PGC1-alpha is induced during mitochondrial biogenesis ac-
companied by adipogenesis to complement the requirement 
of ATP and acetyl-CoA for lipogenesis [98]. Peroxisomal 
trans-2-enoyl-CoA reductase (PECR) catalyzes the conver-
sion of phytol to phytanoyl-CoA in peroxisomes. It has been 
shown that phytanic acid, a derivative of phytol, induces 
adipocyte differentiation in human pre-adipocytes suggesting 
that PECR may serve as an activator of retinoid X receptors 
(RXR) or PPAR [99, 100]. Thus, down-regulation of PGC1-
alpha and PECR by HCA-SX treatment may act in concert to 
promote the anti-adipogenic effect of HCA-SX resulting in 
weight loss.  
  HCA-SX treatment also significantly decreased the ex-
pression of endothelial lipase (LIPG) gene in human adipo-
cytes. Over-expression of LIPG decreases the plasma level 
of high-density lipoprotein (HDL) cholesterol. Since HDL 
level is inversely associated with risk of atherosclerotic car-
diovascular disease, reduction in HDL plasma level is likely 
to produce adverse effects that augment the risk factors for 
cardiovascular diseases [101]. In addition, HDL hydrolysis 
by endothelial lipase (gene product of LIPG) activates 
PPAR which in turn induces inflammation [102]. There-
fore, down-regulation of LIPG by HCA-SX may be benefi-
cial for lipoprotein metabolism and vascular health. 
  Elongation of very-long-chain fatty acids-like 3 (ELOVL 
3) gene was suppressed in human adipocytes by HCA-SX 
treatment. ELOVL3 protein is involved in fatty acid biosyn-
thesis [103]. It has been shown that ELOVL3 gene expres-
sion is significantly induced during adipogenesis. The gene 
product of ELOVL3 catalyzes the synthesis of very-long-
chain fatty acids and triglycerides in the adipose tissues, thus 
facilitating the process of adipogenesis [104]. Therefore, 
Table 3.  HCA-SX Specific Candidate Genes in Human Adipocytes 
Down-Regulated Genes*  Function 
Matrix metallopeptidase 1  Matrix protein turnover 
Matrix metallopeptidase 3  Matrix protein turnover 
Matrix metallopeptidase 10  Matrix protein turnover 
Plasminogen activator  Cell migration, tissue remodeling, fibrinolysis 
Leptin Energy  balance 
Up-Regulated Genes*  Function 
Perilipin  Regulator of lipid storage 
Peroxisome proliferative activated receptor  co-factor 1 Adipogenesis 
Endothelial lipase  Epoxyeicosatrienoic acid metabolism 
Elongation of very-long-chain fatty acids-like 3  Fatty acid biosynthesis 
Epoxide hydrolase 2  Arachidonic acid metabolism 
Peroxisomal trans-2-enoyl-CoA reductase  Fatty acid biosynthesis 
The HCA-SX responsive genes revealed by genome-wide microarray analysis were confirmed by real-time RT-PCR (*P<0.05, as compared to control) [95].  Nutrigenomic Analysis of Weight Management Supplements  Current Genomics, 2008, Vol. 9, No. 4    247 
suppression of ELOVL3 in the human adipocytes by HCA-
SX treatment may inhibit adipogenesis in fat tissues [95].  
  HCA-SX significantly reduced the expression of cyto-
plasmic epoxide hydrolase 2 (EPHX2) gene. EPHX2 gene 
product is involved in the metabolism of arachidonic acid 
[105]. Polymorphisms in EPHX2 gene have been linked to 
the pathogenesis of coronary heart disease (CHD) and athe-
rosclerosis; therefore, EPHX2 has been implicated as a po-
tential cardiovascular disease-susceptibility gene [106, 107]. 
Since obesity is a major risk factor for CHD and atheroscle-
rosis, down-regulation of EPHX2 by HCA-SX in human 
adipocytes may exert protective effect against these cardio-
vascular diseases. 
  Several members of the matrix metalloproteinase (MMP) 
family of protease genes were up-regulated in human adipo-
cytes by HCA-SX treatment (Table 3). Specifically, the ex-
pression of genes encoding MMP1, 3, and 10 proteases was 
stimulated by HCA-SX treatment. MMP proteases play im-
portant role in matrix protein turn-over and tissue remodel-
ing. MMP1 (or interstitial collagenase) and MMP10 (or 
stromelysin 2) play important role in fibrillar collagen and 
proteoglycan metabolism [108]. Proteoglycan turnover has 
been shown to be involved in adipocyte degradation and 
weight loss [109, 110]. MMP3 (or stromelysin 1) has been 
shown to activate MMP1 and impair adipose tissue devel-
opment [111, 112]. Low levels of stromelysins (such as 
MMP3 and MMP10) have been linked to obesity [111, 113]. 
MMP10 degrades extracellular matrix thereby negatively 
regulates angiogenesis and vascular remodeling [114]. Since 
angiogenesis is functionally linked to adipocyte develop-
ment, the anti-angiogenic property of MMP10 may indirectly 
inhibit adipogenesis in the human adipocytes [115]. Induc-
tion of these MMP proteases by HCA-SX treatment may 
exert an anti-angiogenic and anti-adipogenic effect on the 
human adipocytes leading to the observed fat droplet disper-
sion as illustrated in Fig. (4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Hierarchical clustering of HCA-SX sensitive genes. Primary human adipocytes were treated with 0.5 mg/mL of HCA-SX (groups 1-
4) or untreated (groups 5-8). RNA was extracted from each sample and used to assess HCA-SX induced alterations in gene expression with 
human genome microarray (U133 v2.0). HCA-SX-responsive genes were identified as described in Fig. (5). The genes whose expression 
was significantly (P<0.05) changed between the control and the HCA-SX-treated groups were used for hierarchical clustering display with 
the dChip software. Panel A represented up-regulated () while panel B indicated down-regulated () genes by HCA-SX supplementation. 
Image used with permission from Mary Ann Liebert, Incorporated [95]. 248    Current Genomics, 2008, Vol. 9, No. 4  Lau et al. 
  Tissue-type plasminogen activator (PLAT) regulates fi-
brinolysis and is the primary cellular defense mechanism 
against thrombosis [116]. Elevated risk of arterial thrombosis 
is associated with adiposity. It has been shown that the re-
lease of PLAT from the endothelium of obese and over-
weight adults is significantly reduced [116]. The finding 
from the current study showed that treatment of human adi-
pocytes with HCA-SX increased the expression of PLAT 
gene suggesting that HCA-SX may contribute to the restora-
tion of endothelial fibrinolytic dysfunction associated with 
overweight and obesity. 
  The adipocyte-derived hormone leptin together with its 
receptor are the major components in the maintenance of 
energy balance [117, 118]. Disruption of leptin signaling 
pathway through the deletion of leptin receptor has resulted 
in obesity [119]. A large body of evidence also indicates that 
leptin plays important functions in fat oxidation, weight loss, 
and cardioprotection [120, 121]. Microarray analysis, con-
firmed by real-time RT-PCR, showed that the expression of 
leptin in the human adipocytes was significantly up-regula- 
ted by HCA-SX treatment. 
  Taken together, the animal as well as the human adipo-
cyte studies utilizing the nutrigenomic approach demon-
strated for the first time the molecular link between the ob-
served anti-lipolytic and anti-adipogenic effects of HCA-SX 
supplementation and the genomic response to such supple-
mentation.  
4. CONCLUSION  
  Until recently, nutritional research has suffered from the 
incapability of delineating the mechanisms of diet-gene 
regulations. The advent of nutrigenomics has provided the 
tools for the understanding of diet-gene interaction at the 
molecular level. Accumulating physiological evidence has 
indicated safe and efficacious use of NBC and HCA-SX in 
weight management. However, it is not until recently that 
gene-modulation by NBC and HCA-SX, as revealed by 
nutrigenomics approach, has begun to come to light. These 
physionutrigenomics studies represent a novel and powerful 
approach in nutritional sciences which not only elucidates 
the underlying molecular mechanisms but also evaluates the 
health and safety concerns related to the consumption of 
these dietary supplements. Indeed, cDNA microarray tech-
nology provides an extremely efficient means to assess the 
genome-wide alterations in transcriptomes of biological sys-
tems in response to any given therapeutic regimen [122]. In 
this regard, physionutrigenomics holds the promise to facili-
tate the design and development of novel and safe nutraceu-
ticals and functional foods to combat obesity and other 
metabolic disorders.  
  In addition, nutrigenomics is beginning to pave the way 
for personalized nutrition as more associations between die-
tary components and gene regulations are being identified by 
this functional genomics approach. Moreover, through fur-
ther understanding of the biological impacts of nutrient-gene 
modulations, nutrigenomics will provide key insights into 
the pathogenesis and progression of diet-related disorders. 
  Nutritherapeutics combined with a healthy life-style may 
be the most cost-effective and organic way to combat obesity 
epidemic. Through systematic physiological and biochemical 
approaches, the safety and efficacy of NBC and HCA-SX in 
weight management have been demonstrated in chapter. The 
studies discussed here also offer unequivocal evidence that it 
is possible to use the powerful tool of nutrigenomics to deci-
pher the molecular basis for the observed beneficial effects 
of dietary supplements. 
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